Karin Smyth – 2016 Parliamentary Question to the Department of Health

The below Parliamentary question was asked by Karin Smyth on 2016-01-04.

To ask the Secretary of State for Health, when his Department plans to make a decision on whether to refer for consideration by NICE PRRNT treatment for pancreatic cancers.

George Freeman

The National Institute for Health and Care Excellence (NICE) has recently consulted stakeholders on the suitability of Lutetium-177 Dotatate – a type of peptide receptor radionuclide therapy (PRRT) – for treating unresectable, somatostatin receptor-positive gastroentero-pancreatic neuroendocrine tumours without disease progression for referral to its technology appraisal work programme. A decision on its referral to NICE will be taken shortly.